News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioRelix, Inc. and Dalton Medicinal Chemistry Partners Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology



11/13/2007 2:43:57 PM

NEW HAVEN, CT, and TORONTO, Nov. 13 /CNW/ - BioRelix, pioneers in the discovery and development of RiboSwitch based therapeutic agents and Dalton Medicinal Chemistry, have jointly announced a research collaboration to discover new therapeutics.

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES